个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Patterns of treatment failure for PD-(L)1 refractory extensive-stage small cell lung cancer in continued PD-(L)1 treatment

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Liu Li[1,2,3] * ; Liu Tong[1,2,3] ; Wang Xingwen[4] ; Wang Jianbo[5] ; Wang Jun[6] ; Yuan Meng[7] ; Yang Yunxin[1,2] ; Zhang Yingying[1,2] ; Wang Hang[2,8] ; Hu Pingping[1,2,3] ; Zhang Jiandong[1,2,3,*1] ;
机构： [1]Department of Oncology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China [2]Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, China [3]Medical Integration and Practice Center, Cheeloo College of Medicine, Shandong University, Jinan, China [4]Department of Radiotherapy, Cancer Center, Shandong Provincial Hospital, Shandong University, Jinan, China [5]Deprtment of Radiation Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China [6]Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China [7]Department of Oncology, Shandong Provincial Qianfoshan Hospital, Weifang Medical University, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, China [8]Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong First Medical University, Jinan, China
出处：
DOI： 10.1016/j.tranon.2023.101687
ISSN：

关键词： Extensive-stage small cell lung cancer (ESSCLC) Immunotherapy Patterns of failure

摘要：
Although immunotherapy greatly extends overall survival (OS) of patients with extensive-stage small cell lung cancer (ES-SCLC), a number of patients develop immunotherapy resistance (IR). Patterns of failure in ES-SCLC are not clarified. Our study aims to explore the clinical pattern of IR and prognostic factors for these patients.The study was conducted from 117 ES-SCLC patients with immunotherapy between 2018 and 2022. Chi-square tests and Fishers' exact tests was used to explore failure patterns in different populations. Survival analyses of different progression patterns and subsequent treatment regimens were conducted by Kaplan-Meier curves and log-rank test.86 (73.5%) patients experienced IR. The patients with smoking (never smoker vs. current or ex-smoker, 59.5 % vs. 81.3%, P = 0.010), liver metastasis (extrahepatic metastasis vs. intrahepatic metastasis, 73.6 % vs. 90.9%, P = 0.050), and distant metastasis status (no distant metastasis vs. distant metastasis, 39.1 % vs. 81.9%, P<0.001) were associated with IR rates. Liver progression had a lower incidence in 1st line immunotherapy (1st line vs. ≥2nd lines, 14.0 % vs. 41.7%, P = 0.004) and a higher incidence in multiple progression (multiple progression vs. Oligo-progression, 39.4 % vs. 17.0%, P = 0.021). Cranial (41.7 % vs. 16.1%, P = 0.012) and distant lymph node (16.7 % vs. 3.2%, P = 0.049) progression were the main failure model for acquired IR in comparison to primary IR. Patients with new lesion progression only (17.73 vs. 9.17 months, P = 0.013) and non-hepatic progression (14.23 vs. 11.67 months, P = 0.042) had a longer OS. Patients in cross-line immunotherapy after IR had a favourable prognosis (17.07 vs. 11.93 months, P = 0.007).The most common failure pattern of immunotherapy for ES-SCLC was lung and regional lymph node progression. Brain and liver progression were the most common extra thoracic failure sites for 1st line and 2nd and more lines immunotherapy, respectively. There was a higher probability of primary IR in 2 lines and above immunotherapy. Patients with new only progression site and cross-line rechallenge immunotherapy had a better prognosis.Copyright © 2023. Published by Elsevier Inc.

基金：
This study was funded by the National Natural Science Foundation of China (No. 81803043) and Shandong Natural Science Foundation (No. ZR2021LSW023, ZR2021QH356, ZR2022MH111 and ZR2022MH103).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院分区：
出版当年[2023]版：
大类 | 2 区 医学
小类 | 3 区 肿瘤学
最新[2025]版：
大类 | 3 区 医学
小类 | 3 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of Oncology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China [2]Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, China [3]Medical Integration and Practice Center, Cheeloo College of Medicine, Shandong University, Jinan, China
通讯作者：
通讯机构： [1]Department of Oncology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China [2]Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, China [3]Medical Integration and Practice Center, Cheeloo College of Medicine, Shandong University, Jinan, China [*1]Department of Oncology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China.
推荐引用方式(GB/T 7714)：
Liu Li,Liu Tong,Wang Xingwen,et al.Patterns of treatment failure for PD-(L)1 refractory extensive-stage small cell lung cancer in continued PD-(L)1 treatment[J].TRANSLATIONAL ONCOLOGY.2023,33:doi:10.1016/j.tranon.2023.101687.
APA：
Liu Li,Liu Tong,Wang Xingwen,Wang Jianbo,Wang Jun...&Zhang Jiandong.(2023).Patterns of treatment failure for PD-(L)1 refractory extensive-stage small cell lung cancer in continued PD-(L)1 treatment.TRANSLATIONAL ONCOLOGY,33,
MLA：
Liu Li,et al."Patterns of treatment failure for PD-(L)1 refractory extensive-stage small cell lung cancer in continued PD-(L)1 treatment".TRANSLATIONAL ONCOLOGY 33.(2023)

相关文献

[1]Patterns of failure and long-term outcome of postoperative radiotherapy on the survival of patients with pathological T3N0M0 esophageal cancer [2]Analysis of failure patterns in patients with resectable esophageal squamous cell carcinoma receiving chemoradiotherapy [3]Patterns and Mechanisms of Artificial Kidney Failure during Continuous Renal Replacement Therapy [4]Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure [5]可手术切除食管癌单纯三维适形放疗失败原因分析 [6]接受选择性淋巴结照射的食管鳞癌患者预后和失败模式的分析 [7]基于右胸径路完全两野/三野清扫的胸段食管癌术后治疗失败模式分析 [8]Primary breast diffuse large B-cell lymphoma in the rituximab era: therapeutic strategies and patterns of failure (vol 109, pg 3943, 2018) [9]食管癌放疗后达完全缓解患者的失败模式分析 [10]临床无转移食管鳞癌肿瘤局部因素对治疗失败模式的影响

资源点击量：39770 今日访问量：0 总访问量：1333 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号